Is fluconazole (Diflucan) safe for a 13‑year‑old?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Is Fluconazole (Diflucan) Safe in a 13-Year-Old?

Yes, fluconazole is safe for a 13-year-old and is FDA-approved for use in pediatric patients from birth through 17 years of age for multiple indications including oropharyngeal candidiasis, esophageal candidiasis, systemic Candida infections, and cryptococcal meningitis. 1

FDA-Approved Pediatric Use

The FDA label explicitly confirms safety and efficacy in adolescents:

  • Fluconazole has been studied in 577 pediatric patients aged 1 day to 17 years who received doses ranging from 1 to 15 mg/kg/day for durations up to 1,616 days 1
  • An open-label randomized controlled trial demonstrated effectiveness specifically in pediatric patients 6 months to 13 years of age for oropharyngeal candidiasis 1
  • Pharmacokinetic studies established dose proportionality between pediatric patients and adults, supporting appropriate dosing across age groups 1

Safety Profile in Adolescents

The safety data for 13-year-olds is robust:

  • In a systematic review of 4,209 pediatric patients, only 10.3% reported treatment-related side effects, with gastrointestinal symptoms (7.7%) and skin reactions (1.2%) being most common 2
  • Hepatotoxicity occurred in 47.6% of all adverse events reported, but when compared to placebo and other antifungals, the relative risk was not statistically different (RR 1.36,95% CI 0.87-2.14, P=0.175) 2
  • Complete resolution of hepatotoxicity was achieved in 84% of patients with available follow-up 2
  • Only 3.2% of children discontinued treatment due to side effects, mainly gastrointestinal symptoms 3

Age-Specific Considerations for 13-Year-Olds

At 13 years of age, your patient falls into an important therapeutic category:

  • For children under 13 years, echinocandins, voriconazole, or itraconazole are suggested options for antifungal prophylaxis based on efficacy and adverse effects 4
  • For patients 13 years and older, posaconazole becomes an additional option for mold-active prophylaxis 4
  • This age distinction in guidelines reflects pharmacokinetic and safety data supporting broader azole options in adolescents

Common Adverse Effects to Monitor

While fluconazole is safe, clinicians should monitor for:

  • Gastrointestinal symptoms (nausea, vomiting, diarrhea) - most common side effects 2, 3
  • Transient liver enzyme elevations: ALT (4.9%), AST (2.7%), alkaline phosphatase (2.3%) 3
  • Self-limiting hepatobiliary effects occurred in only 0.5% of pediatric patients 3
  • Treatment-related laboratory abnormalities are uncommon and typically transient 3

Drug Interactions

Although 98.6% of pediatric patients in safety studies were taking concomitant medications, no clinical or laboratory interactions were observed 3. However, be aware that:

  • Five reports of drug interactions occurred in children in the systematic review, which can result in significant toxicity 2
  • Monitor for interactions with medications metabolized by CYP450 enzymes

Dosing Considerations

Standard pediatric dosing applies to 13-year-olds:

  • For oropharyngeal candidiasis: 6 mg/kg on day 1, followed by 3 mg/kg/day 1
  • Dose and age did not appear to influence the incidence or pattern of side effects in pediatric studies 3
  • The shorter serum half-life in children (16.8-18.1 hours) compared to adults warrants attention to dosing intervals 5

Clinical Efficacy Data

Fluconazole demonstrates excellent efficacy in adolescents:

  • In pediatric patients with confirmed systemic Candida infections, 83% achieved clinical cure or improvement 6
  • Pathogen eradication occurred in 73% of cases with confirmed fungal infections 6
  • Efficacy in children mirrors the excellent profile seen in adults 3

Key Pitfalls to Avoid

  • Do not assume fluconazole is contraindicated in adolescents - it has extensive safety data in this age group
  • Monitor liver function tests if prolonged therapy is needed, though clinically significant hepatotoxicity is rare
  • Consider that adolescents may require adult-equivalent dosing based on weight rather than age-based calculations
  • Remember that fluconazole is predominantly renally excreted, so adjust dosing if renal impairment is present 1

References

Research

Safety of fluconazole in paediatrics: a systematic review.

European journal of clinical pharmacology, 2013

Research

Safety and tolerability of fluconazole in children.

Antimicrobial agents and chemotherapy, 1999

Research

Fluconazole treatment of children with severe fungal infections not treatable with conventional agents.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 1994

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.